Funding
← Back to your selection

DCVC

Activity from announced rounds

Activity in this selectionBiotech

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$140M
3 disclosed · full round size, not this investor’s share

By stage

Undisclosed2
Series A1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
Kanvas Biosciences

Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy

$48MSeries A
Role not disclosed
Proxima

Develops AI-driven drug discovery for proximity therapeutics

$80MUndisclosed
Role not disclosed